There are currently 78 active clinical trials seeking participants for Renal Cell Carcinoma research studies. The states with the highest number of trials for Autism participants are California, Texas, New York and Florida.
Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
NCT04495894
Recruiting
This is a pilot study of biomarker evaluation and safety of pre-incisional ketorolac for patients undergoing surgical resection for non-small cell lung cancer and renal cell carcinoma. There is significant promise in the use of preoperative ketorolac to decrease the inflammatory response after surgical resection of tumors, thereby potentially reducing the risk of distant metastatic tumor spread and improving survival. A total of 56 patients (28 per disease site) will be enrolled into the experim... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
10/23/2023
Locations: Emory University Hospital Midtown, Atlanta, Georgia +3 locations
Conditions: Non-small Cell Lung Cancer, Renal Cell Carcinoma
Register for Updates
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
NCT04322955
Recruiting
The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: The Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +3 locations
Conditions: Kidney Cancer, Renal Cell Carcinoma
Register for Updates
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
NCT04989959
Recruiting
This is an exploratory study to assess [18F]PT2385 Positron Emission Tomography/Computed Tomography (PET/CT) in patients with renal cell carcinoma (RCC). This is an open-label, nontherapeutic trial. The main objective is to correlate hypoxia-inducible factor-2alpha (HIF2α) levels as determined by an investigational [18F]PT2385 PET/CT scan with the levels on subsequently obtained tissue by HIF2α immunohistochemistry (IHC). There will be three cohorts. The first pre-surgical cohort will have [18F]... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
NCT04883827
Recruiting
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
09/14/2023
Locations: Tennessee Valley Health Care System, Nashville, Tennessee +2 locations
Conditions: Renal Cell Carcinoma
Register for Updates
Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma
NCT04669860
Recruiting
The purpose of the study is to identify bacterial and fungal microbiome associated with calcium oxalate (CO) urolithiasis and renal cell carcinoma (RCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/11/2023
Locations: University of Miami, Miami, Florida
Conditions: Calcium Oxalate Urolithiasis, Renal Cell Carcinoma
Register for Updates
Study of Kidney Tumors in Younger Patients
NCT00898365
Recruiting
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Gender:
All
Ages:
29 years and below
Trial Updated:
09/06/2023
Locations: Children's Hospital of Alabama, Birmingham, Alabama +247 locations
Conditions: Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Register for Updates
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
NCT04495257
Recruiting
This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/13/2023
Locations: Yale Cancer Center, New Haven, Connecticut +1 locations
Conditions: Advanced Melanoma, Renal Cell Carcinoma
Register for Updates
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT04787042
Recruiting
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona +6 locations
Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Register for Updates
Drug Screening Using Novel IMD in Renal Cell Carcinoma
NCT05700461
Recruiting
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC). The name of the intervention(s) involved in this study are: Implantable Microdevice (IMD) Surgery (excision of tumor) Drugs used in this study will only include drugs already used as standard of care for... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer
Register for Updates
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
NCT04006522
Recruiting
This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-DFO-Atezolizumab immunoPET/CT with programmed death-ligand 1 (PD-L1) expression and the response to immune checkpoint inhibitor therapy in patients with RCC. There will be two cohorts, one made up of p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/01/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Renal Cell Carcinoma
Register for Updates
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT03172754
Recruiting
This is a Phase I/II, open-label, multi-center study of axitinib in combination with nivolumab in patients with previously treated and untreated advanced RCC. This clinical study will be composed of a dose finding phase (Phase I) and two parallel dose expansion phases (Phase II). The dose finding phase will assess the safety of the combination and establish a recommended phase II dose (RP2D, the highest tested dose that is declared safe and tolerable by the Investigators and the Sponsor Investig... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2023
Locations: Johns Hopkins, Baltimore, Maryland +3 locations
Conditions: Renal Cell Carcinoma
Register for Updates
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
NCT05733715
Recruiting
This study will evaluate the effect of investigational drugs, pembrolizumab alone or pembrolizumab with lenvatinib, on the immune systems response to kidney cancer when given before and after surgery to remove kidney cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2023
Locations: Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Renal Cell Carcinoma
Register for Updates